Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

D-Cycloserine Enhanced Imaginal Exposure Therapy for Post-Traumatic Stress Disorder (PTSD)

Clinical Trial Details

The purpose of this study is to treat symptoms of post-traumatic stress disorder (PTSD) resulting from various traumas using traditional treatment combined with the use of D-Cycloserine (DCS). 

Treatment is offered on an individual basis for 12-14 weekly sessions lasting approximately 75-90 minutes each. This cognitive-behavioral treatment aims to introduce skills and techniques that will reduce symptoms and improve quality of life. One essential component of the treatment includes describing one's traumatic experience. Participants will be randomly assigned to take either a low dose of D-Cycloserine (DCS; a broad-spectrum antibiotic) or a placebo pill prior to their weekly session to examine the effects of DCS on treatment. Thus treatment incorporates traditional techniques that have been shown to be effective in treating PTSD, with cutting edge pharmacology to enhance the treatment. Treating clinicians are all highly experienced in working with PTSD, civilians and disaster workers. 

Key Eligibility: 

Inclusion Criteria

  • English-speaking
  • Between the ages of 18 and 70
  • Survivors of a variety of traumas (e.g., motor vehicle and accidents, burns and other injuries, combat, World Trade Center attack, etc.)
  • Diagnosed with PTSD
  • In good health. For persons with chronic injuries/ conditions related to their accidents, good health is defined as the injury being in a state of stabilization and able to attend weekly outpatient sessions. 

Exclusion Criteria 

  • Current organic mental disorder
  • Schizophrenia or symptoms of psychosis/delusions
  • Bipolar disorder
  • Current substance abuse or dependence
  • Active suicidal/homicidal ideation, intent, or plan
  • Use of pacemaker
  • Significant health impairment including renal disease
  • Taking oral anticoagulant medication, ethionamide, isoniazid, or anti-depressant medication
  • Hypersensitivity to cycloserine
  • History of seizures
  • Pregnant or currently trying to conceive or breastfeeding

Study contact by location

Upper East Side - Manhattan


Mariel Emrich



Mariel Emrich

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment

Age Group